V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 270014655 | 270010457 | null | null | Curative (C) | 2018-04-07 | 2018-04-07 | FEC 100 | N | N | 270022119 | CETUXIMAB + OXALIPLATIN |
| 270014656 | 270010457 | 1.74 | 86 | null | 2014-02-03 | 2014-02-07 | Lenalidomide 25mg (Cycle 1 to 25) | N | null | 270022119 | PACLITAXEL |
| 270014657 | 270010458 | 1.56 | 70.8 | Palliative (P) | 2015-06-21 | 2015-06-23 | Docetaxel 75mg/m2 (21 day) | 02 | N | 270022130 | CETUXIMAB + CISPLATIN + FU |
| 270014658 | 270010459 | 1.61 | 67.4 | Disease modification (D) | 2017-10-02 | 2017-10-02 | Docetaxel | N | N | 270022133 | CARBOPLATIN + RT |
| 270014659 | 270010461 | 1.67 | 73 | Curative (C) | 2015-05-09 | 2015-06-12 | EVEROLIMUS | N | N | 270022153 | IFOSFAMIDE |
| 270014660 | 270017213 | 1.76 | null | Curative (C) | 2014-05-14 | 2014-05-14 | GemCarbo Days 1+8 | N | null | 270022158 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 270014661 | 270010464 | 1.58 | 48 | Curative (C) | 2014-09-29 | 2014-09-30 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | 270022158 | GEMCARBO |
| 270014662 | 270010464 | null | 61.9 | Curative (C) | 2014-08-20 | 2014-09-29 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | N | 270022158 | RALTITREXED |
| 270014663 | 270010464 | 1.78 | 70.5 | Curative (C) | 2017-08-24 | 2017-09-05 | Raltitrexed | N | N | 270022158 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 270014664 | 270010468 | 1.9 | 53 | Curative (C) | 2016-05-07 | 2016-05-11 | CETUXIMAB + IRINOTECAN | 2 | N | 270022244 | CARBOPLATIN + ETOPOSIDE |
| 270014665 | 270010470 | 1.73 | 84.45 | Curative (C) | null | 2015-05-04 | Bevacizumab + Cape + Oxali 21day | N | N | 270022247 | DOCETAXEL |
| 270014666 | 270014895 | 1.79 | 84.45 | Curative (C) | 2017-07-12 | 2017-07-13 | OXALIPLATIN + MDG + PANITUMUMAB | 02 | N | 270022247 | CARBO + FLUOROURACIL |
| 270014667 | 270010472 | 1.6 | 47 | null | 2014-10-04 | 2014-10-06 | Procarbazine | 02 | N | 270022281 | THALIDOMIDE |
| 270014668 | 270010473 | 1.72 | 73.9 | Curative (C) | 2014-05-01 | 2014-05-14 | ECHELON 1 TRIAL | N | N | 270022281 | CAP + RT |
| 270014669 | 270010476 | 1.71 | null | null | null | 2015-05-28 | CARBOPLATIN + GEMCITABINE | N | null | 270022283 | OXALIPLATIN |
| 270014670 | 270010478 | null | 65.9 | Palliative (P) | 2017-03-02 | 2017-05-26 | Cetuximab+Irinotecan (Cyc2 onwards) | 02 | N | 270022312 | CARBOPLATIN + CETUXIMAB + FU |
| 270014671 | 270010479 | null | 72 | Curative (C) | 2015-12-05 | 2015-12-18 | Vinorelbine (oral) | N | N | 270022325 | SCOT TRIAL |
| 270014672 | 270010480 | 1.68 | 107 | Curative (C) | 2015-08-05 | 2015-08-17 | CHLVPP PABLOE | N | N | 270022325 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA |
| 270014673 | 270018535 | 1.71 | 58 | Curative (C) | 2016-08-16 | 2016-08-21 | PMitCEBO | 2 | N | 270022352 | BLEOMYCIN |
| 270014674 | 270010483 | 1.73 | 90 | Curative (C) | 2016-06-13 | 2016-06-13 | DOXORUBICIN | N | N | 270022352 | CVD |
| 270014675 | 270010484 | 1.65 | 56 | Curative (C) | 2018-04-02 | 2018-04-30 | DHAP - R | N | null | 270022424 | GEMCARBO |
| 270014676 | 270010486 | 1.79 | 75.5 | Curative (C) | 2013-09-05 | 2013-09-08 | CARBOPLATIN + GEMCITABINE | N | N | 270022443 | METHOTREXATE |
| 270014677 | 270010487 | 1.71 | 70 | Curative (C) | 2017-11-29 | 2017-11-29 | Y-90 | 02 | N | 270022458 | DACARBAZINE |
| 270014678 | 270010488 | null | null | Curative (C) | 2014-09-02 | 2014-09-16 | BENDAMUSTINE + CYTARABINE + ETOPOSIDE + MELPHALAN | null | N | 270022471 | DACARBAZINE |
| 270014679 | 270010489 | null | 59.45 | Curative (C) | 2016-05-12 | 2016-10-15 | CHOP - 21 days | N | null | 270022471 | EVEROLIMUS |
| 270014680 | 270010489 | 1.8 | 139.2 | Curative (C) | 2018-03-01 | 2018-03-04 | CVP R | 02 | N | 270022471 | RATHL TRIAL |
| 270014681 | 270010490 | null | 63.6 | null | 2015-07-20 | 2015-07-25 | RATHL TRIAL | N | null | 270022530 | BENDAMUSTINE + RITUXIMAB |
| 270014682 | 270010490 | 1.81 | 72.9 | Curative (C) | 2015-01-28 | 2015-02-05 | R GCVP | N | N | 270022530 | METHOTREXATE INTRATHECAL |
| 270014683 | 270010491 | 1.88 | 63.35 | Curative (C) | 2014-11-02 | 2014-11-02 | ECHELON 1 TRIAL | N | N | 270022540 | HYDROXYCARBAMIDE |
| 270014684 | 270010493 | 1.84 | null | Curative (C) | 2015-09-06 | 2015-10-20 | CHLVPP PABLOE | N | N | 270022550 | RATHL TRIAL |
| 270014685 | 270010494 | 1.54 | null | Curative (C) | 2015-08-01 | 2015-08-12 | DACARBAZINE + DOXORUBICIN + VINBLASTINE | 02 | null | 270022551 | ETOPOSIDE |
| 270014686 | 270010495 | 1.83 | 76.4 | Curative (C) | 2015-11-24 | 2015-12-04 | NHL 2003 Gp B COPADM 1 & 2 | N | N | 270022551 | FLUDARABINE + MELPHALAN |
| 270014689 | 270010498 | 1.76 | 64.3 | Curative (C) | 2013-07-31 | 2013-08-06 | NHL 2003 Gp B COP | N | N | 270022619 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 270014690 | 270010500 | 1.62 | 92 | Palliative (P) | 2017-07-29 | 2017-08-01 | BLEOMYCIN | 02 | N | 270022634 | CTD |
| 270014691 | 270014904 | 1.74 | null | Palliative (P) | 2016-11-10 | 2016-11-19 | LACE | N | N | 270022647 | ICE-R |
| 270014692 | 270010503 | 1.58 | 56 | Neo-adjuvant (N) | 2015-01-11 | 2015-01-14 | ICE-R | N | N | 270022660 | CVP R |
| 270014693 | 270010503 | null | 81 | Curative (C) | 2016-07-29 | 2016-07-31 | Etoposide IV | 02 | N | 270022660 | CHLVPP/PABLOE |
| 270014694 | 270010503 | 1.65 | 43.8 | Disease modification (D) | 2018-01-22 | 2018-01-22 | MELPHALAN | 02 | N | 270022660 | DOCETAXEL |
| 270014695 | 270010505 | 1.58 | 81 | Adjuvant (A) | 2015-05-08 | 2015-06-07 | Etoposide IV | N | N | 270022695 | IBRUTINIB |
| 270014696 | 270010505 | 1.7 | 70.6 | null | 2014-02-28 | 2014-03-14 | Hydroxycarbamide | 2 | null | 270022695 | METHOTREXATE INTRATHECAL |
| 270014697 | 270010507 | 1.73 | 70 | Curative (C) | null | 2018-05-21 | CARBOPLATIN + GEMCITABINE | N | N | 270022706 | MELPHALAN |
| 270014698 | 270017223 | 1.69 | 50.8 | Adjuvant (A) | 2015-10-27 | 2015-10-27 | Cisplatin + Etoposide + RT | 2 | N | 270022723 | CAP + RT |
| 270014699 | 270010508 | 1.73 | 70 | Curative (C) | 2014-09-04 | 2014-09-06 | CYCLOPHOSPHAMIDE | 2 | N | 270022794 | BENDAMUSTINE + BRENTUXIMAB |
| 270014700 | 270014908 | 1.64 | 83.3 | Not known (9) | 2014-01-08 | 2014-01-12 | R GCVP | N | N | 270022796 | GEMCITABINE + OXALIPLATIN |
| 270014701 | 270010510 | 1.94 | 89.8 | Disease modification (D) | 2017-10-13 | 2017-10-13 | VINCRISTINE | 02 | N | 270022812 | LENALIDOMIDE |
| 270014702 | 270010511 | null | null | Curative (C) | null | 2014-08-31 | ICE (no GCSF) | 99 | N | 270022820 | LENALIDOMIDE |
| 270014703 | 270010511 | null | 67.8 | null | 2017-05-26 | 2017-07-15 | Hydroxycarbamide | 02 | null | 270022820 | LENALIDOMIDE |
| 270014704 | 270018538 | 1.65 | 63.4 | Adjuvant (A) | 2014-02-22 | 2014-03-02 | CTD | 2 | N | 270022858 | DACARBAZINE |
| 270014705 | 270010513 | 1.82 | 63.8 | Curative (C) | 2018-06-03 | 2018-06-04 | CYCLOPHOSPHAMIDE | N | N | 270022864 | HYDROXYCARBAMIDE |
| 270014706 | 270010514 | 1.7 | 70 | Neo-adjuvant (N) | 2018-05-17 | 2018-05-18 | ECHELON 1 TRIAL | 02 | N | 270022895 | CYCLOPHOSPHAMIDE + FLUDARABINE |